Hepatic stellate cells: It's role in normal and pathological conditions;Las células estrelladas del hígado: Su importancia en condiciones normales y patológicas

Gastroenterologia y Hepatologia

Volumn 29, Issue 2, 2006, Pages 93-101

  Sarem, M ^a,b   Znaidak, R ^a   Macias M ^b   Rey, R ^b  

^a INSTITUTO DE INVESTIGACIONES EN INGENIERÍA GENÉTICA Y BIOLOGÍA MOLECULAR   (Argentina)

^b Argentina   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOTENSIN II; ANTIFIBROTIC AGENT; ANTIVIRUS AGENT; COLCHICINE; COLLAGEN; ENDOTHELIN 1; GAMMA INTERFERON; GLIOTOXIN; GLYCOPROTEIN; HERBACEOUS AGENT; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; NATRIURETIC FACTOR; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROSTAGLANDIN E1; PROTEOGLYCAN; RETINOID; SILYMARIN; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; VASOPRESSIN;

CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL STRUCTURE; CHRONIC DISEASE; DRUG MECHANISM; EXTRACELLULAR MATRIX; FIBROGENESIS; HUMAN; LIVER BLOOD FLOW; LIVER CELL; LIVER CELL DAMAGE; LIVER FIBROSIS; MYOFIBROBLAST; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; STELLATE CELL;

EID: 33644525672     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13083906     Document Type: Article

References (109)

1. Wake K. Karl Wilhelm Kupffer and his contributions to modern hepatology comparative. Hepatology. 2004;3 Suppl 1:2.
2. Ramadori G. The stellate cell (Ito-cell, fat-storing cell, lipocyte, perisinusoidal cell) of the liver. New insights into pathophysiology of an intriguing cell. Virchows Arch B Cell Pathol Incl Mol Pathol. 1991;61:147-58.
3. Eastman JT, DeVries AL. Hepatic ultrastructural specialization in Antarctic fishes. Cell Tissue Res. 1981;219:489-96.
4. a ed. Madrid: McGraw-Hill Interamericana de España S.A.; 1995. p. 919-91.
5. Geerts A, Schuppan D, Lazeroms S, De Zanger R, Wisse E. Collagen type I and III occur together in hybrid fibrils in the space of Disse of normal rat liver. Hepatology. 1990;12:233-41.
6. Bioulac-Sage P, Lafon ME, Saric J, Balabaud C. Nerves and perisinusoidal cells in human liver. J Hepatol. 1990;10:105-12.
7. Griffiths MR, Keir S, Burt AD. Basement membrane proteins in the space of Disse: a reappraisal. J Clin Pathol. 1991;44: 646-8.
8. Senoo H. Structure and function of hepatic stellate cells. Med Electron Microsc. 2004;37:3-15.
9. Safadi R, Friedman SL. Hepatic fibrosis-role of hepatic stellate cell activation. Med Gen Med. 2002;4:27.
10. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis. 2001;21:311-35.
11. Suematsu M, Asio S. Professor Toshio Ito: a clairvoyant in pericyte biology. Keio J Med. 2001;50:66-71.
12. Blomhoff R, Rasmussen M, Nilsson A, Norum KR, Berg T, Blaner WS, et al. Hepatic retinol metabolism. Distribution of retinoids, enzymes, and binding proteins in isolated rat liver cells. J Biol Chem. 1985;260:13560-5.
13. Yamada M, Blaner WS, Soprano DR, Dixon JL, Kjeldbye HM, Goodman DS. Biochemical characteristics of isolated rat liver stellate cells. Hepatology. 1987:7:1224-9.
14. Nagy NE, Holven KB, Roos N, Senoo H, Kojima N, Norum KR, et al. Storage of vitamin A in extrahepatic stellate cells in normal rats. J Lipid Res. 1997;38:645-58.
15. Sato M. Suzuki S, Senoo H. Hepatic stellate cell: unique characteristics in cell biology and phenotype. Cell Struct Funct. 2003;28:105-12.
16. Kawada N. The hepatic perisinusoidal stellate cell. Histol Histpathol. 1997;12:1069-80.
17. Thimgan MS, Yee HF Jr. Quantitation of rat hepatic stellate cell contraction: stellate cells' contribution to sinusoidal resistance. Am J Physiol. 1999;277:G137-G43.
18. Sous Herruzo JA. Factores involucrados en la fibrogénesis hepática. Gastroenterol Hepatol. 2000;26:186-99.
19. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis. 2001;21:397-416.
20. Benlloch S, Beltrán B. Moreno R, Berenguer M. Fibrogénesis y trasplantc hepático. Gastroenterol Hepatol. 2003;26:381-95.
21. Gressner AM, Bachern MG. Cellular sources of noncollagenous matrix proteins: role of fat-storing cells in fibrogenesis. Semin Liver Dis. 1990;10:30-46.
22. Hautekeete ML, Geerts A. The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Arch. 1997;430:195-207.
23. Bonis PA, Friedman SL, Kaplan MM. Is liver fibrosis reversible? N Engl J Med. 2001;344:452-4.
24. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000; 275:2247-50.
25. Iredale JP. Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol. 1997;29:43-54.
26. Arthur MJ, Mann DA, Iredale JP. Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. J Gastroenterol Hepatol. 1998;13 Supl:33-8.
27. Gressner AM. Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. Kidney Int Suppl. 1996;54:S39-S45.
28. Casu A, Canepa M, Nanni G. Perisinusoidal stellate cells or Ito cells and their role in hepatic fibrosis. Pathologica. 1994; 86:467-99.
29. Joya-Vázquez PP, Bruguera M, Sánchez-Tapias JM, Ampurdanés S, Ventura PJ. La progresion de la fibrosis hepática en la hepatitis C crónica. Gastroenterol Hepatol. 2000;23:1-6.
30. Enzan H, Himeno H, Saibara T, Hara H. Recent studies on Ito cells with molecular biology. Nippon Rinsho. 1993;51:472-81.
31. García Buey L, Garcia Monzon C, Moreno Otero R. Los mediadores de la inflamacion y la hepatitis crónica. Gastroenterol Hepatol. 1995;18:42-54.
32. Pinzani M, Marra F, Carloni V. Signal transduction in hepatic stellate cells. Liver. 1998;18:2-13.
33. Li D, Friedman SL. Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. J Gastroenterol Hepatol. 1999;14:618-33.
34. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci. 2002;7:793-807.
35. Casini A, Pinzani M, Milani S, Grappone C, Galli G, Jezequel AM, et al. Regulation of extracellular matrix synthesis by transforming growth factor beta 1 in human fat-storing cells. Gastroenterology. 1993;105:245-53.
36. Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA. The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo. J Hepatol. 1999;30:77-87.
37. Border WA, Noble NA. Transforming growth factor b in tissue fibrosis. N Engl J Med. 1994;331:1286-92.
38. Wells RG. Fibrogenesis V. TGF-β signaling pathways. Am J Physiol Gastrointest Liver Physiol. 2000;279:G845-G50.
39. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev. 2000;14:627-44.
40. Bachem MG, Meyer D, Melchior R, Sell KM, Gressner AM. Activation of rat liver perisinusoidal lipocytes by transforming growth factors derived from myofibroblastlike cells. A potential mechanism of self perpetuation in liver fibrogenesis. J Clin Invest. 1992;89:19-27.
41. Bachem MG, Sell KM, Melchior R, Kropf J, Eller T, Gressner AM. Tumor necrosis factor alpha (TNF alpha) and transforming growth factor beta 1 (TGF beta 1) stimulate fibronectin synthesis and the transdifferentiation of fat-storing cells in the rat liver into myofibroblasts. Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;63:123-30.
42. Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA. The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo. J Hepatol. 1999;30:77-87.
43. Chai Q, Krag S, Miner JH, Nyengaard JR, Chai S, Wogensen L. TGF-beta1 induces aberrant laminin chain and collagen type IV isotype expression in the glomerular basement membrane. Nephron Exp Nephrol. 2003;94:e123-e36.
44. Neubauer K, Kruger M, Quondamatteo F, Knittel T. Saile B, Ramadori G. Transforming growth factor-beta1 stimulates the synthesis of basement membrane proteins laminin, collagen type IV and entactin in rat liver sinusoidal endothelial cells. J Hepatol. 1999;31:692-702.
45. Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P. et al. TGF-beta in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis Am J Physiol. 1999;276:G1059-G68.
46. Moller-Pedersen T, Cavanagh HD, Petroll WM, Jester JV. Neutralizing antibody to TGFbeta modulates stromal fibrosis but not regression of photoablative effect following PRK. Curr Eye Res. 1998;17:736-47.
47. Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2000;279:G245-G9.
48. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of stellate cells. Semin Liver Dis. 2001;21:373-84.
49. Knittel T, Mehde M, Kobold D, Saile B. Dinter C, Ramadori G. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non parenchymal cell of rat liver. Regulation by TNF-α and TGF-β1. J Hepatol. 1999;30: 48-60.
50. McCrudden R, Iredale JP. Liver fibrosis, the hepatic stellate cell and tissue inhibitors of metalloproteinases. Histol Histopathol. 2000;15:1159-68.
51. Sakaida I, Hironaka K, Kimura T, Terai S, Yamasaki T, Okita K. Herbal medicine Sho-saiko-to (TJ-9) increases expression matrix metalloproteinases (MMPs) with reduced expression of tissue inhibitor of metalloproteinases (TIMPs) in rat stellate cell. Life Sci. 2004;74:2251-63.
52. Herbst H, Wege T, Milani S, Pellegrini G, Orzechowski HD, Bechstein WO, et al. Tissue inhibitor of metalloproteinases-1 and 2 RNA expression in rats and human liver fibrosis. Am J Pathol. 1997;150:1647-59.
53. Iredale JP, Murphy G, Hembry RM, Friedman SL, Arthur MJ. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. J Clin Invest. 1992;90:282-7.
54. Iredale JP, Goddard S, Murphy G, Benyon RC, Arthur MJ. Tissue inhibitor of metalloproteinase-1 and interstitial collagenase expression in autoimmune chronic active hepatitis and activated human hepatic lipocytes. Clin Sci (Lond). 1995;89:75-81.
55. Iredale JP, Benyon RC, Arthur MJ, Ferris WF, Alcolado R, Winwood PJ, et al. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology. 1996;24:176-84.
56. Benyon RC, Iredale JP, Goddard S, Winwood PJ, Arthur MJP. Expression of tissue inhibitor of metalloproteinases-1 and -2 is increased in fibrotic human liver. Gastroenterology. 1996;110:821-31.
57. Huet PM, Villeneuve JP, Pomier-Layrargues G, Marleau D. Hepatic circulation in cirrhosis. Clin Gastroenterol. 1985;14: 155-68.
58. Griffiths MR, Keir S, Burt AD. Basement membrane proteins in the space of Disse: a reappraisal. J Clin Pathol. 1991;44: 646-8.
59. Martínez-Hernández A, Martínez J. The role of capillarization in hepatic failure: studies in carbon tetrachloride-induced cirrhosis. Hepatology. 1991;14:864-74.
60. Zimmermann A, Zhao D, Reichen J. Myofibroblasts in the cirrhotic rat liver reflect hepatic remodeling and correlate with fibrosis and sinusoidal capillarization. J Hepatol. 1999;30: 646-52.
61. Neubauer K, Saile B, Ramadori G. Liver fibrosis and altered matrix synthesis. Can J Gastroenterol. 2001;15:187-93.
62. Xiao W, Wang Y, Liu X. The coordinated expression of laminin and its integrin receptor in hepatic sinusoidal capillarization. Zhonghua Nei Ke Za Zhi. 2001;40:618-20.
63. Urashima S, Tsutsumi M, Nakase K, Wang JS, Takada A. Studies on capillarization of the hepatic sinusoids in alcoholic-liver disease. Alcohol Alcohol Suppl. 1993;1B:77-84.
64. Bhunchet E, Fujieda K. Capillarization and venularization of hepatic sinusoids in porcine serum-induced rat liver fibrosis: a mechanism to maintain liver blood flow. Hepatology. 1993; 18:1450-8.
65. Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology. 1997;25:2-5.
66. Kelley C. D'Amore P, Hechtman HB, Shepro D. Microvascular pericyte contractility in vitro: comparison with other cells of the vascular wall. J Cell Biol. 1987;104:483-90.
67. Rockey DC. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis. 2001;21:337-49.
68. Zhang JX, Pegoli W Jr, Clemens MG. Endothelin-1 induces direct constriction of hepatic sinusoids. Am J Physiol. 1994; 266(4 Pt 1):G624-32.
69. Reynaert H, Thompson MG, Thomas T, Geerts A. Hepatic-stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut. 2002;50:571-81.
70. McCuskey RS. Morphological mechanisms for regulating blood flow through hepatic sinusoids. Liver. 2000;20:3-7.
71. Clemens MG, Zhang JX. Regulation of sinusoidal perfusion: in vivo methodology and control by endothelins. Semin Liver Dis. 1999;19:383-96.
72. Kawada N, Tran-Thi TA, Klein H, Decker K. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem. 1993;213:815-23.
73. Ramadori G, Veit TH, Shwogler S, Dienes HP, Knittel T, Rieder H, et al. Expression of the gene of a-smooth muscle actin isoform in rat liver and in rat fat-storing (ITO) cells. Virchows Arch B Cell Pathol Incl Mol Pathol. 1990;59:349-57.
74. Schmitt-GrAff A, Krüger S, Bochard F, Gabbiani G, Denk H. Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am J Pathol. 1991;138:1233-42.
75. Carloni V, Romanelli RG, Pinzani M, Laffi G, Gentilini P. Expression and function of integrin receptors for collagen and laminin in cultured human hepatic stellate cells. Gastroenterology. 1996;110:1127-36.
76. Racine-Samson L, Rockey DC, Bissell DM. The role of alpha1beta1 integrin in wound contraction. A quantitative analysis of liver myofibroblasts in vivo and in primary culture. J Biol Chem. 1997;272:30911-7.
77. Bataller R, Nicolas JM, Ginees P, Gorbig MN, Garcia-Ramallo E, Lario S, et al. Contraction of human hepatic stellate cells activated in culture: a role for voltage-operated calcium channels. J Hepatol. 1998;29:398-408.
78. Bataller R, Gasull X, Ginés P, Hellemans K, Gorbig MN, Nicolas JM, et al. In vitro and in vivo activation of rat hepatic stellate cells results in de novo expression of L-type voltage-operated calcium channels. Hepatology. 2001;33:956-62.
79. Yanagisawa M, Kurihara S, Kumura Y, Tomobe Y, Kobayashi M, Mitsui Y. et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-5.
80. Masaki T, Yanagisawa M, Goto K. Physiology and pharmacology of endothelins. Med Res Rev. 1992;12:391-421.
81. Gandhi CR, Behal RH, Harvey SA, Nouchi TA, Olson MS. Hepatic effects of endothelin. Receptor characterization and endothelin-induced signal transduction in hepatocytes. Biochem J. 1992;287:897-904.
82. Housset C, Rockey DC, Bissell DM. Endothelin receptors in rat liver: lipocytes as a contractile target for endothelin 1. Proc Natl Acad Sci U S A. 1993;90:9266-70.
83. Tran-Thi TA, Kawada N, Decker K. Regulation of endothelin-1 action on the perfused rat liver. FEBS Lett. 1993;318: 353-7.
84. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology. 199624:233-40.
85. Reichen J, Gerbes AL, Steiner MJ, Sagesser H, Clozel M. The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol. 1998;28:1020-30.
86. a ed. Barcelona: Editorial Masson S.A.; 1997. p. 343-53.
87. Wei H, Lu H, Li D, Zhan Y, Wang Z, Huang X. The expression of AT1 receptor on hepatic stellate cells in rat fibrosis induced by CC14. Chin Med J (Engl). 2001;114:583-7.
88. Batailer R, Ginés P, Nicolas JM, Gorbig MN, García-Ramallo E, Gasull X, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 2000;118:1149-56.
89. Zhang Y, Yang X, Wu P, Xu L, Liao G, Yang G. Expression of angiotensin II type 1 receptor in rat hepatic stellate cells and its effects on cell growth and collagen production. Horm Res. 2003;60:105-10.
90. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakalani T, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 2001;34:745-50.
91. Kurikawa N, Suga M, Kuroda S, Yamada K, Ishikawa H. An angiotensin II type I receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol. 2003;139:1085-94.
92. Bataller R, Sancho-Bru P, Ginés P, Lora JM, Al-Garawi A, Sole M, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 2003;125:117-25.
93. Baik SK, Jo HS, Suk KT, Kim JM, Lee BJ, Choi YJ, et al. Inhibitory effect of angiotensin II receptor antagonist on the contraction and growth of hepatic stellate cells. Korean J Gastroenterol. 2003;42:134-41.
94. Bataller R, Nicolas JM, Ginés P, Esteve A, Nieves Gorbig M, Garcia-Ramallo E, et al. Arginine vasopressin induces contraction and stimulates growth of cultured human hepatic stellate cells. Gastroenterology. 1997;113:615-24.
95. Islam MZ, Williams BC, Madhavan KK, Hayes PC, Hadoke PW. Selective alteration of agonist-mediated contraction in hepatic arteries isolated from patients with cirrhosis. Gastroenterology. 2000;118:765-71.
96. Decker K. The response of liver macrophages to inflammatory stimulation. Keio J Med. 1998;47:1-9.
97. Bredt DS, Snyder SH. Nitric oxide a physiologic messenger molecule. Annu Rev Biochem. 1994;63:175-95.
98. Marietta MA. Nitric oxide synthase structure and mechanism. J Biol Chem. 1993;268:12231-4.
99. Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol. 2000;190:244-54.
100. Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide a physiologic messenger. Ann Intern Med. 1994;120:227-37.
101. Mittal MK, Gupta TK, Lee FY, Sieber CC, Groszmann RJ. Nitric oxide modulates hepatic vascular tone in normal rat liver. Am J Physiol. 1994;267:G416-G22.
102. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology. 1998;28:926-31.
103. Albanis EL, Safadi RL, Friedman SL. Treatment of hepatic fibrosis. Almost there. Curr Gastroenterol Rep. 2003;5:48-56.
104. Friedman SL. Liver fibrosis-from bench to bedside. J Hepatol. 2003;38:38-53.
105. Waring P, Beaver J. Gliotoxin and related epipolythiodioxopiperazines. Gen Pharmacol. 1996;27:1311-6.
106. Peralta O, Lagunas A, Madrid V. Transforming growth factor beta-1: structure, function, and regulation mechanisms in cancer. Salud Publica Mex. 2001;43:340-51.
107. Prud'homme GJ, Piccirillo CA. The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases. J Autoimmun. 2000;14:23-42.
108. Everett L, Galli A, Crabb D. The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. Liver. 2000;20:191-9.
109. Beljaars L, Meijer D, Poelstra K. Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis. Front Biosci. 2002;7:e214-e22.